An Observer-blind, Dose Ranging Safety and Immunogenicity Study of GSK Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Influenza A virus H5N1 vaccines (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 09 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Feb 2018.
- 09 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Nov 2016 Planned End Date changed from 1 Jan 2018 to 1 Feb 2018.